Consumption of Dietary Premna microphylla Turcz Leaf Alleviates Functional Constipation via Regulating Gut Microbiota

Nan Wang1, Mengxue Zhang1, Li Zhang1

  • 1Key Laboratory of Ministry of Education for Medicinal Resource and Natural Pharmaceutical Chemistry, College of Life Sciences, Shaanxi Normal University, Xi'an 710119, China.

PubMed

Insights

This study shows that a novel pectic polysaccharide from Premna microphylla Turcz leaves (PMTL) effectively prevents constipation. PMTL normalizes gut microbiota, reduces inflammation, and improves intestinal function, making it a promising dietary supplement for constipation relief.

Area of Science:

  • Pharmacology and Toxicology
  • Gastroenterology
  • Natural Product Chemistry

Background:

  • Constipation is a prevalent gastrointestinal disorder with significant impact on quality of life.
  • Current treatments for constipation have limitations and side effects.
  • Natural compounds are being explored for their therapeutic potential in managing constipation.

Purpose of the Study:

  • To investigate the preventive effects of a novel pectic polysaccharide from Premna microphylla Turcz leaves (PMTL) on experimental constipation.
  • To elucidate the underlying mechanisms of PMTL's action in alleviating constipation.

Main Methods:

  • A diphenoxylate-induced constipation model (CM) in rats was established.
  • Rats were fed a standard diet supplemented with varying doses of PMTL (5%, 10%, 20%) for six weeks.
  • Intestinal peristalsis, fecal water content, gut morphology, neurotransmitter levels, colonic aquaporin expression, gut microbiota composition (16S rRNA sequencing), and fecal short-chain fatty acids were analyzed.

Main Results:

  • PMTL supplementation significantly accelerated intestinal peristalsis and increased fecal water content in CM rats.
  • PMTL suppressed gut inflammation by modulating excitatory and inhibitory neurotransmitter secretions and normalizing colonic aquaporin expression (AQP3, AQP4).
  • PMTL administration relieved gut microbiota disorders, promoted beneficial bacteria, and increased fecal short-chain fatty acids.

Conclusions:

  • Dietary PMTL consumption effectively ameliorates the development of experimental constipation.
  • PMTL demonstrates potential as a promising dietary supplement for alleviating constipation through multiple mechanisms, including gut microbiota modulation and anti-inflammatory effects.

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
698
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
523
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
618
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
1.0K
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
562
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
871